IL6 and myocardial infarction: The Norwegian tocilizumab non–ST‐segment–elevation MI (NSTEMI) trial, the first human study of IL‐6 blockade in MI,7 was a 2‐center, randomized, double‐blind, placebo‐controlled trial that enrolled 121 patients with NSTEMI.